Veronica Bernard
Overview
Explore the profile of Veronica Bernard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Witte H, Kunstner A, Hahn T, Bernard V, Stolting S, Kusch K, et al.
Ann Hematol
. 2025 Feb;
PMID: 39992429
In classic Hodgkin-lymphoma (cHL), only a few cases recur, and only a limited fraction of patients is primary-refractory to standard-polychemotherapy. Underlying genomic features of unfavorable clinical courses remain sparsely characterized....
2.
Denker S, Kunstner A, Schwarting J, Witte H, Bernard V, Stolting S, et al.
Leukemia
. 2024 Jun;
38(8):1858-1861.
PMID: 38890446
No abstract available.
3.
Kunstner A, Schwarting J, Witte H, Xing P, Bernard V, Stolting S, et al.
Leukemia
. 2024 Apr;
38(5):1086-1098.
PMID: 38600314
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive malignancy originating from plasmacytoid dendritic cells (pDCs) with a primarily cutaneous tropism followed by dissemination to the bone marrow...
4.
Witte H, Riedl J, Kunstner A, Fahnrich A, Ketzer J, Fliedner S, et al.
Target Oncol
. 2023 Jul;
18(5):749-765.
PMID: 37488307
Background: There is growing evidence supporting multidisciplinary molecular tumor boards (MTB) in solid tumors whereas hematologic malignancies remain underrepresented in this regard. Objective: The present study aimed to assess the...
5.
Witte H, Fahnrich A, Kunstner A, Riedl J, Fliedner S, Reimer N, et al.
Front Oncol
. 2023 Mar;
13:1129405.
PMID: 36923431
Introduction: Hematologic malignancies are currently underrepresented in multidisciplinary molecular-tumor-boards (MTB). This study assesses the potential of precision-oncology in primary-refractory plasmablastic-lymphoma (prPBL), a highly lethal blood cancer. Methods: We evaluated clinicopathological...
6.
Kunstner A, Schwarting J, Witte H, Bernard V, Stolting S, Kusch K, et al.
Blood Cancer J
. 2022 Jul;
12(7):101.
PMID: 35788129
No abstract available.
7.
Witte H, Merz H, Bernd H, Bauer A, Bernard V, Feller A, et al.
Leuk Lymphoma
. 2021 Dec;
63(4):894-902.
PMID: 34856873
Gray-zone lymphoma (GZL) reflects an aggressive B-cell neoplasm with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL). The International Prognostic Index (IPI) and its derivatives...
8.
Kunstner A, Witte H, Riedl J, Bernard V, Stolting S, Merz H, et al.
Haematologica
. 2021 Nov;
107(8):1850-1863.
PMID: 34788985
High-grade B-cell lymphoma accompanied with double/triple-hit MYC and BCL2 and/or BCL6 rearrangements (HGBLDH/ TH) poses a cytogenetically-defined provisional entity among aggressive B-cell lymphomas that is traditionally associated with unfavorable prognosis....
9.
Witte H, Kunstner A, Hertel N, Bernd H, Bernard V, Stolting S, et al.
Blood Adv
. 2021 Oct;
6(2):637-651.
PMID: 34714908
Plasmablastic lymphoma (PBL) represents a clinically heterogeneous subtype of aggressive B-cell non-Hodgkin lymphoma. Targeted-sequencing studies and a single-center whole-exome sequencing (WES) study in HIV-positive patients recently revealed several genes associated...
10.
Gebauer N, Kunstner A, Ketzer J, Witte H, Rausch T, Benes V, et al.
Blood Cancer J
. 2021 May;
11(5):102.
PMID: 34039950
Epstein-Barr virus (EBV)-associated diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) constitute a distinct clinicopathological entity in the current World Health Organization (WHO) classification. However, its genomic features remain...